Highlights

• H1 FY2026 underlying EBIT grew 7.3% and underlying net profit rose 8.1%, led by the Australian division.

• Hospital admissions rose 3.1% and higher-margin surgical admissions climbed 5.7%.

• The Interim Dividend was lifted 6.3% to 42.5 cents fully franked, a payout of about 60% of underlying earnings.

• Operating Cash Flow rose almost 17% to roughly $350 million.

• Ramsay plans to distribute its 52.8% stake in Ramsay Sante to shareholders, with implementation targeted for the December quarter of 2026.

• Ramsay Sante's provisional annual accounts showed European Revenue of about EUR 5.38 billion, up 3.3%, but a net loss of EUR 48.3 million.

• Funding-group Leverage sat at 2.22 times, inside the company's 2.5-times target, with Fitch reaffirming a BBB- rating.

After three years in which its private-hospital Economics were squeezed between stubborn cost Inflation and slow-moving payer indexation, Ramsay Health Care has become one of the more closely watched names in a broad rerating of ASX healthcare stocks. The country's largest private hospital operator lifted underlying Earnings at its February half-year result, is pressing ahead with a plan to hand shareholders its French business, and is due to report full-year FY2026 numbers at the end of August. For investors the question is whether the operational momentum of the first half marks a genuine turn, or merely a pause in a long grind.

Latest Developments

At its half-year result to 31 December 2025, Ramsay reported underlying EBIT growth of 7.3 per cent and underlying net profit up 8.1 per cent, with the Australian division doing the heavy lifting as hospital admissions rose 3.1 per cent and higher-margin surgical admissions climbed 5.7 per cent. The board lifted the interim dividend 6.3 per cent to 42.5 cents fully franked, at a payout of about 60 per cent of underlying earnings, while operating cash flow rose almost 17 per cent to roughly $350 million.

The defining strategic move remains the proposed demerger of Ramsay Sante. Ramsay intends to distribute its 52.8 per cent stake in the listed French operator to its own shareholders, with implementation targeted for the December quarter of 2026, leaving a simpler, more Australia and UK-weighted group. Ramsay Sante's own provisional annual accounts, released in late August, showed European revenue of about EUR 5.38 billion, up 3.3 per cent, but a net loss attributable to owners of EUR 48.3 million, underscoring why the parent wants to separate the two stories.

What the Numbers Show

The half-year told a story of Margin repair rather than a boom. Australian revenue rose 8.2 per cent and divisional EBIT 7.1 per cent, helped by improved indexation and a 23 per cent jump in clinical-trials activity. The UK acute Business grew revenue 3.5 per cent in constant currency and expanded margins, while Ramsay Sante managed 4.4 per cent EBIT growth despite the loss of a French government revenue guarantee that cost it around EUR 20 million.

Balance-sheet discipline is central to the thesis. Funding-group leverage sat at 2.22 times, inside the company's 2.5-times target, and Fitch reaffirmed its BBB- investment-grade rating. Management guided to net financing costs of roughly $590-610 million and an underlying effective tax rate near 35 per cent for the year, a reminder that interest and tax continue to absorb much of the operating recovery.

What Could Drive the Stock Next

The Ramsay Sante distribution is the clearest catalyst; completing it would leave a cleaner group and remove the drag of French funding politics from the headline result. The proposed Acquisition of National Capital Private Hospital in Canberra, flagged as earnings-per-share accretive within its first year, and additional UK funding anticipated from April 2026 also feed the recovery case.

The imminent full-year FY2026 result will test whether second-half momentum held. Investors will focus on whether Australian Volume and indexation trends continued, on UK NHS activity, and on the pace of cost-outs at underperforming Assets such as the Elysium mental-health operations in Britain, where beds and sites have been closed.

Key Risks to Watch

France remains the standout risk. Continued public-funding constraints and minimal Tariff increases have kept Ramsay Sante loss-making at the bottom line, and the demerger still requires board, shareholder, court and regulatory approvals before it can complete.

Closer to home, high financing costs, a heavy capital-expenditure program and any softening in private-health-insurance participation could all blunt the earnings rebound. Execution on hospital-network reconfiguration and UK turnaround programs is far from finished.

Investor Takeaway

Ramsay's first-half figures and its move to spin off Ramsay Sante suggest a company finally simplifying itself around a recovering core, and the coming full-year result will show how durable that improvement is. Whether the long-awaited turnaround is truly real, rather than merely under way, is a judgement each investor will weigh against Ramsay's still-elevated Debt and unresolved European questions.

This article is general information only and does not constitute financial or Investment advice.